Adefovir (formerly known as PMEA and GS-0393; trade names Preveon and Hepsera) is a potent DNA polymerase inhibitor with the potential for the treatment of HBV infection.

Lersivirine (formerly UK-453061; UK453061) is a novel next-generation and potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with IC50 of 119 nM and a unique resistance profile.

Telbivudine (Epavudine; L-Thymidine; NV 02B; LDT 600; trade name:Tyzeka; Epavudine ) is a potent, and selective HBV (hepatitis B virus) reverse transcriptase inhibitor used primarily in the treatment of hepatitis B infection.

Zalcitabine (trade name Hivid) is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI).

MK-2048 is a potent and second-generation inhibitor of integrase (IN) and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively.

Adefovir Dipivoxil (also known as GS 0840 and GS-0840; trade names Preveon and Hepsera), the dipivoxil formulation of adefovir, is a reverse transcriptase inhibitor, used in the treatment of chronic hepatitis B virus (HBV).

Tenofovir Disoproxil Fumarate (TDF; GS-433105; Viread; Tenofovir DF), the Fumarate salt of tenofovir, belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5′-triphosphate and, after incorporation into DNA, by DNA chain termination.

Raltegravir (formerly also known as MK-0518; trade name: Isentress) is a novel, potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively.

Foscarnet Sodium (also known as Phosphonoformate), an antiherpesvirus agent, inhibits viral RNA polymerases, reverse transcriptase, and DNA polymerases through noncompetitive inhibition with dNTPs.

Tenofovir (formerly also known as GS-1278; PMPA; TDF) is an approved anti-HIV drug that blocks reverse transcriptase and hepatitis B virus infections.